1. Home
  2. Stocks
  3. Pfizer Share Price

Pfizer Share Price

Pharmaceuticals Large Cap

₹5,252.45 +64.2 (1.24%)

05 Nov, 2024 20:57

SIP TrendupStart SIP in PFIZER

Start SIP
Performance Financial Technical Events FnO Shareholding Pattern More FAQ’s

Performance

  • Low
  • ₹5,161
  • High
  • ₹5,272
  • 52 Week Low
  • ₹3,850
  • 52 Week High
  • ₹6,451
  • Open Price₹5,189
  • Previous Close₹5,188
  • Volume12,943

Investment Returns

  • Over 1 Month -6.48%
  • Over 3 Month -7.17%
  • Over 6 Month + 24.73%
  • Over 1 Year + 35.16%
SIP Lightning

Smart Investing Starts Here Start SIP with Pfizer for Steady Growth!

Pfizer Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 38.9
  • PEG Ratio
  • 2.1
  • Market Cap Cr
  • 24,029
  • P/B Ratio
  • 6.7
  • Average True Range
  • 180.1
  • EPS
  • 119.7
  • Dividend Yield
  • 0.7
  • MACD Signal
  • -124.26
  • RSI
  • 38.92
  • MFI
  • 20.62

Pfizer Financial

IndicatorSep 24Jun 24Mar 24Dec 23Sep 23
Net Sales/Income from operations588.59562.86546.63539.97575.21
Total Income From Operations588.59562.86546.63539.97575.21
P/L Before Interest, Excpt. Items & Tax217.33204.73250.81170.85203.25
P/L Before Exceptional Items & Tax215.23202.62243.86167.99200.52
P/L After Tax from Ordinary Activities158.35150.71178.86129.98148.96
Net Profit/Loss For the Period158.35150.71178.86129.98148.96
IndicatorMar 24Mar 23
Revenue From Operations [Gross]2,192.692,422.32
Revenue From Operations [Net]2,192.692,422.32
Total Operating Revenues2,193.172,424.76
Total Revenue2,373.682,525.81
Total Expenses1,635.561,734.80
Profit/Loss Before Tax746.07824.01
Profit/Loss For The Period551.33623.93
IndicatorMar 24Mar 23
Net CashFlow - Operating Activity256.84355.68
Net Cash Used In Investing Activity53.70-36.05
Net Cash Used in Finance Activity-235.14-345.79
Net Inc/Dec In Cash And Equivalent75.40-26.16
Cash And Equivalent End Of Year112.0036.60
IndicatorMar 24Mar 23
Total Share Capital45.7545.75
Total Non-Current Liabilities86.68136.08
Total Current Liabilities546.56657.35
Total Capital And Liabilities4,228.784,000.73
Total Non-Current Assets1,459.221,475.64
Total Current Assets2,769.562,525.09
Total Assets4,228.784,000.73
Indicator20242023
EBIT Margin (%)34.3533.17
Return On Capital Employed (%)20.4624.05
Return On Equity (%)15.3319.45
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)785.91701.05
IndicatorNov 08Nov 07
Revenue From Operations [Gross]790.92798.57
Revenue From Operations [Net]733.20735.60
Total Operating Revenues733.20735.60
Total Revenue799.221,055.47
Total Expenses591.89588.70
Profit/Loss Before Tax207.33466.76
Profit/Loss For The Period299.57340.00
IndicatorNov 08Nov 07
Net CashFlow - Operating Activity237.7616.45
Net Cash Used In Investing Activity-78.87232.53
Net Cash Used in Finance Activity-95.20-75.90
Net Inc/Dec In Cash And Equivalent63.69173.09
Cash And Equivalent End Of Year543.61479.91
IndicatorNov 08Nov 07
Total Share Capital29.8429.84
Total Non-Current Liabilities3.014.50
Total Current Liabilities196.55217.74
Total Capital And Liabilities1,100.65871.97
Total Non-Current Assets109.2591.32
Total Current Assets991.41780.64
Total Assets1,100.65871.97
Indicator20242023
EBIT Margin (%)34.3533.17
Return On Capital Employed (%)20.4624.05
Return On Equity (%)15.3319.45
Long Term Debt To Equity (%)0.000.00
Book Value/Share (INR)785.91701.05

Pfizer Technicals

EMA & SMA

Current Price
₹5,252.45
+ 64.2 (1.24%)
pointer
  • stock-down_img
  • Bullish Moving Average 6
  • stock-up_img
  • Bearish Moving Average 10
  • 20 Day
  • ₹5,394.17
  • 50 Day
  • ₹5,522.09
  • 100 Day
  • ₹5,392.22
  • 200 Day
  • ₹5,061.39

Resistance and Support

5228.52 Pivot Speed
  • R3 5,406.83
  • R2 5,339.42
  • R1 5,295.93
  • S1 5,185.03
  • S2 5,117.62
  • S3 5,074.13

Is Pfizer Worth Buying?

BUY SELL HOLD

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Pfizer is a global pharmaceutical company offering innovative medicines and vaccines across therapeutic areas, including oncology, cardiology, and infectious diseases. It operates in India, focusing on enhancing patient access to advanced treatments and healthcare solutions. Pfizer (Nse) has an operating revenue of Rs. 2,238.05 Cr. on a trailing 12-month basis. An annual revenue de-growth of -6% needs improvement, Pre-tax margin of 34% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 81 which is a GOOD score indicating consistency in earnings, a RS Rating of 48 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation. (+)

Pfizer Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-28 Quarterly Results
2024-07-29 Quarterly Results
2024-05-17 Audited Results & Final Dividend
2024-02-09 Quarterly Results
2023-10-28 Quarterly Results
Date Purpose Remarks
2024-08-21 FINAL Rs.35.00 per share(350%)Final Dividend
2023-08-11 FINAL Rs.35.00 per share(350%)Final Dividend
2023-08-11 SPECIAL Rs.5.00 per share(50%)Special Dividend
2022-09-20 SPECIAL Rs.30.00 per share (300%) Special Interim Dividend
2022-08-19 FINAL Rs.35.00 per share(350%)Dividend

Pfizer F&O

Pfizer Shareholding Pattern

63.92%
10.43%
5.52%
3.54%
0.01%
12.15%
4.43%
  • NSE Symbol
  • PFIZER
  • BSE Symbol
  • 500680
  • Managing Director
  • Ms. Meenakshi Nevatia
  • ISIN
  • INE182A01018

Pfizer FAQs

Pfizer share price is ₹5,252 As on 05 November, 2024 | 20:43

The Market Cap of Pfizer is ₹24028.8 Cr As on 05 November, 2024 | 20:43

The P/E ratio of Pfizer is 38.9 As on 05 November, 2024 | 20:43

The PB ratio of Pfizer is 6.7 As on 05 November, 2024 | 20:43

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

The Vigilance Awareness Week for the year 2024 (VAW 2024) would be observed from October 28, 2024 to November 03, 2024
“सत्यनिष्ठा की संस्कृनि सेराष्र की समद्ृधि” “Culture of Integrity for Nation's Prosperity”
e-pledge link (https://pledge.cvc.nic.in/)

5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

*Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

Contact Us

Attention Investors

  • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
  • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

Email: support@5paisa.com

Support Desk Helpline: 8976689766

©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.